StreetInsider.com News Articles

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Caligan Partners LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930564.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Caligan Partners LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930564.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26927655.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26927655.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26927506.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26927506.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924094.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924094.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Bleichroeder LP

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921106.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Bleichroeder LP

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921106.html

Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c

Thu, 13 Aug 2026 07:25:19 -0400

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Cellectar Biosciences (CLRB) click here.

Form 8-K Cellectar Biosciences, For: Aug 13

Thu, 13 Aug 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260813/26916433.html

Form 8-K Cellectar Biosciences, For: Aug 13

Thu, 13 Aug 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260813/26916433.html

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 13 Aug 2026 07:15:00 -0400

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program

Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) at the American Society of Clinical Oncology 2026 Annual Meeting

Initiated Enrollment and Dosed First Patients in Phase 1b Clinical Trial of CLR 125 in
Triple Negative Breast Cancer

Announced Publication of Phase 1 Data in Peer-Reviewed Journal Cancers

Company to Hold Webcast and Conference Call at 8:30

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 13 Aug 2026 07:15:00 -0400

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program

Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) at the American Society of Clinical Oncology 2026 Annual Meeting

Initiated Enrollment and Dosed First Patients in Phase 1b Clinical Trial of CLR 125 in
Triple Negative Breast Cancer

Announced Publication of Phase 1 Data in Peer-Reviewed Journal Cancers

Company to Hold Webcast and Conference Call at 8:30

Form 10-Q Cellectar Biosciences, For: Jun 30

Thu, 13 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260813/26916258.html

Form 10-Q Cellectar Biosciences, For: Jun 30

Thu, 13 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260813/26916258.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Empery Asset Management, LP

Tue, 04 Aug 2026 10:06:00 -0400
si-local-file:///var/storage/secattach/20260804/26863497.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Empery Asset Management, LP

Tue, 04 Aug 2026 10:06:00 -0400
si-local-file:///var/storage/secattach/20260804/26863497.html

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Thu, 30 Jul 2026 08:05:00 -0400

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time.

Conference Call & Webcast Details:
Date: Thursday, August 13, 2026
Time:
Conference Call & Webcast Details:
Date: Thursday, August 13, 2026
Time: Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in
Relapsed/Refractory Multiple Myeloma

Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted
Radiotherapeutic Across Multiple B-Cell Malignancies

FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myeloma (r/r MM).

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Wed, 15 Jul 2026 07:30:00 -0400

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in
Relapsed/Refractory Multiple Myeloma

Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted
Radiotherapeutic Across Multiple B-Cell Malignancies

FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myeloma (r/r MM).

Brookline Capital Markets Reinstates Cellectar Biosciences (CLRB) at Buy

Mon, 13 Jul 2026 04:51:14 -0400

Brookline Capital Markets analyst Kumaraguru Raja reinstates coverage on Cellectar Biosciences (NASDAQ: CLRB) with a Buy rating and a price target of $15.00.
For an analyst ratings summary and ratings history on Cellectar Biosciences click here. For more ratings news on Cellectar Biosciences click here.
Shares of Cellectar Biosciences closed at $2.82 yesterday.

Conference Call & Webcast Details:
Date:	Thursday, August 13, 2026
Time:
Conference Call & Webcast Details:
Date:	Thursday, August 13, 2026
Time:	Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiotherapeutic Across Multiple B-Cell Malignancies FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myeloma (r/r MM). Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers Wed, 15 Jul 2026 07:30:00 -0400 Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiotherapeutic Across Multiple B-Cell Malignancies FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myeloma (r/r MM). Brookline Capital Markets Reinstates Cellectar Biosciences (CLRB) at Buy Mon, 13 Jul 2026 04:51:14 -0400 Brookline Capital Markets analyst Kumaraguru Raja reinstates coverage on Cellectar Biosciences (NASDAQ: CLRB) with a Buy rating and a price target of $15.00. For an analyst ratings summary and ratings history on Cellectar Biosciences click here. For more ratings news on Cellectar Biosciences click here. Shares of Cellectar Biosciences closed at $2.82 yesterday.